- Home
- TFX vs LEGN Comparison
TFX vs LEGN Comparison
Compare TFX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFX
- LEGN
- Stock Information
- Founded
- TFX 1943
- LEGN 2014
- Country
- TFX United States
- LEGN United States
- Employees
- TFX N/A
- LEGN N/A
- Industry
- TFX Medical/Dental Instruments
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- TFX Health Care
- LEGN Health Care
- Exchange
- TFX Nasdaq
- LEGN Nasdaq
- Market Cap
- TFX 8.3B
- LEGN 7.0B
- IPO Year
- TFX N/A
- LEGN 2020
- Fundamental
- Price
- TFX $137.81
- LEGN $35.06
- Analyst Decision
- TFX Hold
- LEGN Strong Buy
- Analyst Count
- TFX 9
- LEGN 13
- Target Price
- TFX $193.88
- LEGN $79.17
- AVG Volume (30 Days)
- TFX 1.7M
- LEGN 1.1M
- Earning Date
- TFX 05-01-2025
- LEGN 03-11-2025
- Dividend Yield
- TFX 0.98%
- LEGN N/A
- EPS Growth
- TFX N/A
- LEGN N/A
- EPS
- TFX 1.48
- LEGN N/A
- Revenue
- TFX $3,047,324,000.00
- LEGN $627,241,000.00
- Revenue This Year
- TFX $3.37
- LEGN $66.60
- Revenue Next Year
- TFX $4.13
- LEGN $49.28
- P/E Ratio
- TFX $93.54
- LEGN N/A
- Revenue Growth
- TFX 2.45
- LEGN 119.97
- 52 Week Low
- TFX $128.55
- LEGN $30.17
- 52 Week High
- TFX $249.91
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- TFX 35.19
- LEGN 44.07
- Support Level
- TFX $137.79
- LEGN $34.00
- Resistance Level
- TFX $140.98
- LEGN $36.20
- Average True Range (ATR)
- TFX 3.22
- LEGN 1.52
- MACD
- TFX 1.41
- LEGN -0.25
- Stochastic Oscillator
- TFX 38.44
- LEGN 25.18
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.